SubHero Banner

Lynparza® (olaparib) – Voluntary indication withdrawal

August 26, 2022 - The FDA approved a voluntary indication withdrawal for AstraZeneca’s Lynparza (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

Download PDF